Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell blood cancers with fewer cardiac side effects and flexible dosing options.

Glenmark is set to launch a generic version of Teva’s Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to begin in May 2025. The company will launch ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch[1] of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine ...

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg ...

FDA inspectors found serious problems at a Glenmark factory in India that manufactured the recalled drugs. Another medication made there has been tied to deaths of U.S. patients.

Glenmark is recalling over 25 products due to CGMP deviations, Sun Pharma due to 'cross contamination,' and Zydus due to CGMP deviations.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% ...

Glenmark’s formulation business in India grew by 9.6 per cent in Q3 FY25, surpassing the market’s overall growth of 7.2 per cent. For the 12 months ending December 2024, the company posted a ...

Glenmark Pharmaceuticals on Monday (February 24, 2025) said it will pay USD 7 million to three entities to settle lawsuits in the U.S. related to generic drugs. In a regulatory filing, the Mumbai ...

Glenmark will pay out the settlement fee in six installments over five years, the company said in a filing (PDF) on the Bombay Stock Exchange. The company stressed that the agreement to resolve ...

For the fourth quarter ended March 31, 2023, Glenmark’s consolidated revenue stood at ₹3,063 crore, as compared to ₹3,000 crore, up 2.1 percent over the same period in the previous year.

Glenmark Specialty SA, a subsidiary of Glenmark Pharma, announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will ...